The introduction of anti-tumor necrosis factor alpha (anti-TNF) antibodies to the treatment of inflammatory bowel diseases (IBD) is considered to be one of the most important advances in gastroenterologic therapeutics in recent years. The gene discussed is TNF; the disease is inflammatory bowel disease.